LeukoSite To Begin Phase IIa Asthma Study In 1999 After CytoMed Acquisition
Executive Summary
LeukoSite said it plans to initiate a Phase IIa clinical trial with CytoMed's leukotriene inhibitor CMI-977 in 1999, following the acquisition of the Cambridge, Mass. biopharmaceutical firm.